(S)he said what?!?

In late August, the European Commission approved Boehringer Ingelheim/Eli Lilly’s DPP-4 inhibitor, Tradjenta, for type 2 diabetes. Tradjenta (also known as Trajenta in...

(S)he said what?!?

Recently, increasing evidence has suggested that weight-loss surgery (called “bariatric surgery”) can help improve type 2 diabetes management (or even cause its reversal...

Kelly reflects on her recent visit to Washington…

Although most blood glucose meters are theoretically able to upload test results to a computer, the reality can be a frustrating, time-consuming process. Different...

The diaTribe team traveled to Amsterdam to attend the 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD).

During our recent trip to Portugal for the 47th Annual Meeting of EASD, we had the chance to see the once-weekly GLP-1 drug Bydureon for the first time since its...

Valeritas’ V-Go Disposable Insulin Delivery Device. In late July, Valeritas announced it had received CE Mark approval for its V-Go disposable insulin delivery device,...

With humor and detail, Gary Scheiner, a certified diabetes educator and author of one of our favorite books about diabetes, Think Like a Pancreas, gives us his...

On January 27, the Food and Drug Administration (FDA) granted approval to Bydureon, a new drug for type 2 diabetes that is injected once a week. Approved last year in...

Larry Soler and Dr. James Gavin discuss Partnership for a Healthier America's efforts to fight childhood obesity.

The diaTribe team had an outstanding evening in San Francisco for World Diabetes Day on November 14, which included blue hula hooping in Union Square. (For those who...

While the rest of America was watching the Super Bowl, we were taking in the countryside in Montpellier, France, at first annual European Diabetes Technology and...

In welcome news, the pharmaceutical companies Amylin, Eli Lilly, and Alkermes announced in early July that Bydureon , a drug for people with type 2 diabetes meant to be...

Kerri Morrone Sparling advocates for unity in the diabetes community.

In exciting news, Vivus announced that it intends to resubmit its weight-loss drug Qnexa to the FDA for review by the end of October. As a reminder, in October 2010, the...

In late March, the International Diabetes Federation (IDF) released a "position statement" recommending the consideration of bariatric surgery to treat type 2 diabetes...

Earlier this month, the FDA chose not to approve Bristol-Myers Squibb/AstraZeneca’s dapagliflozin, a member of a class of drugs that causes users to excrete excess...

Nine year-old Boaz Alkalay offers a rare glimpse of diabetes through the eyes of a child.